Opt-out options in new product co-development partnerships

Production and Operations Management

Volumn 23, Issue 8, 2014, Pages 1370-1386

  Savva, Nicos ^a   Scholtes, Stefan ^b  

^a LONDON BUSINESS SCHOOL   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

financial constraints; new product co development; pharmaceutical R D; real options

Indexed keywords

EID: 84906343695     PISSN: 10591478     EISSN: 19375956     Source Type: Journal    
DOI: 10.1111/poms.12059     Document Type: Article

References (43)

1. Aggarwal, V. A., D. H. Hsu,. 2009. Modes of cooperative R&D commercialization by start-ups. Manag. J. 30 (8): 835-864.
2. Agrawal, V., N. Oraiopoulos,. 2012. Contract design for collaborative projects. Working paper, Georgetown University.
3. Anderson, E. G., N. Joglekar,. 2005. A hierarchical modeling framework for product development planning. Prod. Oper. Manag. 14 (3): 344-361.
4. Beggs, A. W,. 1992. The licensing of patents under asymmetric information. Int. J. Ind. Org. 10 (2): 171-191.
5. Bhaskaran, S. R., V. Krishnan,. 2009. Effort, revenue, and cost sharing mechanisms for collaborative new product development. Manage. Sci. 55 (7): 1152-1169.
6. Bhattacharya, S., V. Gaba, S. Hasija,. 2012. The role of milestone-based contracts for coordinating R&D partnerships. INSEAD Working Paper.
7. Chao, R., S. Kavadias,. 2008. A theoretical framework for managing the NPD portfolio: When and how to use strategic buckets. Manage. Sci. 54 (5): 907-921.
8. Choi, J. P., 2001. Technology transfer with moral hazard. Int. J. Ind. Org. 19 (1-2): 249-266.
9. Crama, P., B. De Reyck, Z. Degraeve,. 2008. Milestone payments or royalties? Contract design for R&D licensing. Oper. Res. 56 (6): 1539-1552.
10. Crama, P., B. De Reyck, Z. Degraeve,. 2012. Step by step. The benefits of stage-based R&D licensing contracts. Lee Kong Chian School of Business Working Paper.
11. Danzon, P. M., S. Nicholson, N. S. Pereira,. 2005. Productivity in pharmaceutical-biotechnology R&D: The role of experience and alliances. J. Health Econ. 24 (2): 317-339.
12. DiMasi, J. A., H. G. Grabowski,. 2012. R&D costs and returns to new drug development: A review of the evidence. The Oxford Handbook of the Economics of the Biopharmaceutical Industry. Oxford University Press, New York.
13. DiMasi, J. A., R. W. Hansen, H. G. Grabowski,. 2003. The price of innovation: New estimates of drug development costs. J. Health Econ. 22 (2): 151-185.
14. Edlin, A. S., B. E. Hermalin,. 2000. Contract renegotiation and options in agency problems. J. Law Econ. Org. 16 (2): 395-423. doi: 10.1093/jleo/16.2. 395.
15. Erat, S., S. Kavadias,. 2006. Introduction of new technologies to competing industrial customers. Manage. Sci. 52 (11): 1675-1688.
16. Erat, S., S. Kavadias, C. Gaimon,. 2013. The pitfalls of subsystem integration: When less is more. Manage. Sci. 59 (3): 659-676.
17. Gallini, N. T., B. D. Wright,. 1990. Technology transfer under asymmetric information. RAND J. Econ. 21 (1): 147-160.
18. Girotra, K., K. Ulrich, C. Terwiesch,. 2007. Risk management in new product portfolios: A study of late stage drug failures. Manage. Sci. 53 (9): 1452-1466.
19. Hagedoorn, J., 1993. Understanding the rationale of strategic technology partnering: Interorganizational modes of cooperation and sectoral differences. Strateg. Manag. J. 14 (5): 371-385.
20. Hagedoorn, J., 2002. Inter-firm R&D partnerships: An overview of major trends and patterns since 1960. Res. Policy 31 (4): 477-492.
21. Hagedoorn, J., S. Lorenz-Orlean, H. van Kranenburg,. 2009. Inter-firm technology transfer: Partnership-embedded licensing or standard licensing agreements? Ind. Corp. Change 18 (3): 529-550.
22. Hall, B. H., J. Lerner,. 2010. The financing of R&D and innovation., B. H. Hall, N. Rosenberg, eds. Handbook of the Economics of Innovation. Elsevier-North Holland, Oxford, UK, 609-639.
23. Hauser, J. R., 1998. Research, development, and engineering metrics. Manage. Sci. 44 (12): 1670-1689.
24. Hendricks, K. B., V. R. Singhal,. 1997. Delays in new product introductions and the market value of the firm: The consequences of being late to the market. Manage. Sci. 43 (4): 422-436.
25. Himmelberg, C. P., B. C. Petersen,. 1994. R&D and internal finance: A panel study of small firms in high-tech industries. Rev. Econ. Stat. 76 (1): 38-51.
26. Huchzermeier, A., C. H. Loch,. 2001. Project management under risk: Using the real options approach to evaluate flexibility in R&D. Manage. Sci. 47 (1): 85-101.
27. Hutchison-Krupat, J., S. Kavadias,. 2009. Compensation challenges for cross-functional teams. Working paper.
28. Kamien, M. I., 1992. Patent licensing., R. J. Aumann, S. Hart, eds. Handbook of Game Theory, Vol. 1. Elsevier, Oxford, UK, 331-354.
29. Libaers, D., M. Meyer, A. Geuna,. 2006. The role of university spinout companies in an emerging technology: The case of nanotechnology. J. Technol. Transfer. 31 (4): 443-450.
30. Lou, K., M. de Rond,. 2006. The 'not invented here' myth. Nature Rev. Drug Discovery 5: 451-452.
31. Macho-Stadler, I., X. Martinez-Giralt, J. D. Prez-Castrillo,. 1996. The role of information in licensing contract design. Res. Policy 25 (1): 43-57.
32. Mihm, J., 2010. Incentives in new product development projects and the role of target costing. Manage. Sci. 56 (8): 1324-1344.
33. Mihm, J., C. Loch, A. Huchzermeyer,. 2003. Problem solving oscillations in complex engineering projects. Manage. Sci. 49 (6): 733-750.
34. Müller, A., D. Stoyan,. 2002. Comparison Methods for Stochastic Models and Risks. Wiley, Chichester, England.
35. Santiago, L. P., P. Vakili,. 2005. On the value of flexibility in R&D projects. Manage. Sci. 51 (8): 1206-1218.
36. Savva, N., N. Taneri,. 2011. The equity vs. royalty dilemma in university technology transfer. LBS Working Paper.
37. Schall, L. D., 1972. Asset valuation, firm investment, and firm diversification. J. Bus. 45 (1): 11-28.
38. Schwartz, E. S,. 2004. Patents and R&D as real options. Econ. Notes 33 (1): 23-54.
39. Scotchmer, S., 2004. Innovation and Incentives. The MIT Press, Cambridge, MA.
40. Sen, D., 2005. On the coexistence of different licensing schemes. Int. Rev. Econ. Finan. 14 (4): 393-413.
41. Trigeorgis, L., 1996. Real Options: Managerial Flexibility and Strategy in Resource Allocation. MIT Press, Cambridge, MA.
42. Villiger, R., B. Bogdan,. 2005. Getting real about valuations in biotech. Nature Biotech. 23 (4): 423-428.
43. Xiao, W., Y. Xu,. 2012. The impact of royalty contract revision in a multistage strategic R&D alliance. Manage. Sci. 58 (12): 2251-2271.